StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$28.04−0.55 (-1.92%)

Close on Nov 17, 2026Market cap $2.20BP/E –Yield –

Celldex Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Celldex Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $158.00K, down 97.3% year over year. For fiscal 2025 it was $1.55M, down 78.0% from the year before. Over ten years it grew -11.9% a year on average. The highest annual figure on record is $46.79M in fiscal 2010.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.55M-78.0%
FY2024Dec 31, 2024$7.02M+2.0%
FY2023Dec 31, 2023$6.88M+192.0%
FY2022Dec 31, 2022$2.36M-49.3%
FY2021Dec 31, 2021$4.65M-37.3%
FY2020Dec 31, 2020$7.42M+107.6%
FY2019Dec 31, 2019$3.57M-62.5%
FY2018Dec 31, 2018$9.54M-25.2%
FY2017Dec 31, 2017$12.74M+87.8%
FY2016Dec 31, 2016$6.79M+23.8%
FY2015Dec 31, 2015$5.48M+52.8%
FY2014Dec 31, 2014$3.59M-12.8%
FY2013Dec 31, 2013$4.11M-63.3%
FY2012Dec 31, 2012$11.20M+20.9%
FY2011Dec 31, 2011$9.27M-80.2%
FY2010Dec 31, 2010$46.79M+208.3%
FY2009Dec 31, 2009$15.18M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.00K-97.0%
Q1 FY2026Mar 31, 2026$15.00K-97.8%
Q4 FY2025Dec 31, 2025$121.00K-89.7%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$730.00K-70.8%
Q1 FY2025Mar 31, 2025$695.00K+345.5%
Q4 FY2024Dec 31, 2024$1.18M-71.6%
Q3 FY2024Sep 30, 2024$3.19M+110.3%
Q2 FY2024Jun 30, 2024$2.50M+832.1%
Q1 FY2024Mar 31, 2024$156.00K-83.9%
Q4 FY2023Dec 31, 2023$4.13M+156.1%
Q3 FY2023Sep 30, 2023$1.52M+272.7%
Q2 FY2023Jun 30, 2023$268.00K+64.4%
Q1 FY2023Mar 31, 2023$967.00K+455.7%
Q4 FY2022Dec 31, 2022$1.61M+382.9%
Q3 FY2022Sep 30, 2022$407.00K+166.0%
Q2 FY2022Jun 30, 2022$163.00K-95.3%
Q1 FY2022Mar 31, 2022$174.00K-74.6%
Q4 FY2021Dec 31, 2021$334.00K-91.2%
Q3 FY2021Sep 30, 2021$153.00K-77.1%
Q2 FY2021Jun 30, 2021$3.48M+1374.6%
Q1 FY2021Mar 31, 2021$685.00K-74.9%
Q4 FY2020Dec 31, 2020$3.79M+326.8%
Q3 FY2020Sep 30, 2020$668.00K+22.3%
Q2 FY2020Jun 30, 2020$236.00K-67.0%
Q1 FY2020Mar 31, 2020$2.73M+91.4%
Q4 FY2019Dec 31, 2019$887.00K-49.7%
Q3 FY2019Sep 30, 2019$546.00K-42.0%
Q2 FY2019Jun 30, 2019$715.00K-74.1%
Q1 FY2019Mar 31, 2019$1.43M-65.0%
Q4 FY2018Dec 31, 2018$1.76M-49.0%
Q3 FY2018Sep 30, 2018$941.00K-76.0%
Q2 FY2018Jun 30, 2018$2.76M-27.8%
Q1 FY2018Mar 31, 2018$4.07M+165.2%
Q4 FY2017Dec 31, 2017$3.46M+84.4%
Q3 FY2017Sep 30, 2017$3.92M+76.8%
Q2 FY2017Jun 30, 2017$3.83M–
Q1 FY2017Mar 31, 2017$1.53M–
Q4 FY2016Dec 31, 2016$1.87M–
Q3 FY2016Sep 30, 2016$2.22M–

More Celldex Therapeutics figures

See a number that looks wrong?